Anticoagulation after liver transplantation: A retrospective audit and case-control study

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 615-618

  Widén, Anna ^a,b   Rolando, Nancy ^a,b   Manousou, Pinelopi ^a,b   Rolles, Keith ^a,b   Davidson, Brian ^a,b   Sharma, Dinesh ^a,b   Tuddenham, Edward ^a,b   Burroughs, Andrew K ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Bleeding, fibrosis; Liver transplantation; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANTICOAGULATION; ARTICLE; BLEEDING; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTICOAGULANTS; DATA COLLECTION; DRUG TOXICITY; FEMALE; FIBROSIS; HEMORRHAGE; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN; YOUNG ADULT;

EID: 70449555523     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832c87c8     Document Type: Article

References (22)

1. Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, et al. Coagulation and fibrosis in chronic liver disease.Gut 2008; 57:1722-1727.
2. Neubauer K, Knittel T, Armbrust T, Ramadori G. Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury. Gastroenterology 1995; 108:1124-1135.
3. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21:1238-1247.
4. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21:1232-1237.
5. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003; 52:404-409.
6. Poujol-Robert A, Boë lle PY, Poupon R, Robert A, Factor V. Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology 2004; 39:1174-1175.
7. Anstee QM, Wright M, Goldin R, Thomas HC, Thursz M. The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure. Hepatology 2004; 40:534A-535A.
8. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008; 6:1334-1335.
9. Xu Z, Westrick RJ, Shen YC, Eitzman DT. Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury. Thromb Haemost 2001; 85:441-444.
10. Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168:1358-1365.
11. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475-1482.
12. Cholongitas E, Quaglia A, Samonakis D, Senzolo M, Triantos C, Patch D, et al. Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 2006; 55:1789-1794.
13. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann Intern Med 2003; 139:893-900.
14. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention of nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
15. Czer LS, Chaux A, Matloff JM, DeRobertis MA, NessimSA, Scarlata D, et al. Ten-year experience with the St. Jude Medical valve for primary valve replacement. J Thorac Cardiovasc Surg 1990; 100:44-54.
16. Turpie A, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329:524-529.
17. Ogendo WO. Warfarin-related bleeding following open heart surgery in Nairobi. East Afr Med J 2001; 78:139-143.
18. Prieto M, Berenguer M, Rayó n JM, Có rdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 2003; 29:250-256.
19. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs AK, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45:127-143.
20. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13:733-740.
21. Carrió n JA, Navasa M, Garc?́a-Retortillo M, Garc?́a-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132:1746-1756.
22. Berenguer M. Editorial: recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl 2007; 13:641-643.